NEW YORK (GenomeWeb News) – Luminex today announced a deal with healthcare system Partners HealthCare for the discovery of biomarkers and development of clinical assays.
Partners HealthCare Center for Personalized Genetic Medicine will develop molecular diagnostic assays based on biomarkers discovered within the integrated health system to be run on Luminex's xMAP platform.
Under the terms of the deal, the two partners will evaluate opportunities for assays developed and validated in PCPGM's CLIA-certified Laboratory for Molecular Medicine. Additional terms were not disclosed.
In an e-mail, a spokesman for Partners Healthcare said that it and Luminex are exploring all disease conditions, with a focus on oncology and cardiovascular disease.
Partners HealthCare owns several hospitals, mostly in the Boston vicinity, and was founded in 1994 by Brigham and Women's Hospital and Massachusetts General Hospital.
Patrick Balthrop, president and CEO of Austin, Texas-based Luminex, said in a statement, "[W]e are confident that our joint efforts will drive market innovation and important technology advancements that will help dramatically improve patients' lives in the years ahead."